Nemocnice AGEL Trinec-Podlesi a.s.
12
2
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Mixed Reality in MitraClip Implantation: Preliminary Case Series
Role: lead
Heart Rate Variability and Medication Adherence in Resistant Hypertension
Role: lead
Pilot Validation of the STELA Preventive Medicine Platform to Reduce Modifiable Health Risk Factors in Adults (CPM-STELA)
Role: lead
Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation (HOMA-PULSE)
Role: lead
CT Body Composition as Predictor of Exercise Therapy Outcome in Peripheral Arterial Disease
Role: lead
Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic
Role: collaborator
Pulsed-field Ablation Vs. Sham Ablation to Treat AF
Role: collaborator
Atrial Fibrillation Risk After Miniinvasive Mitral Valve Repair
Role: lead
Radiosurgery of Ganglion StELlatum In Patients With REFractory Angina Pectoris
Role: collaborator
Pulsed-field Ablation for Patients With Asymptomatic Non-paroxysmal Atrial Fibrillation
Role: collaborator
Comparison of Two DCCV Algorithms - Rational Versus Maximum Fixed Energy
Role: lead
Overal Survival After TAVI According to Sarcopenia
Role: lead
All 12 trials loaded